All Stories

  1. “But that is your opinion”: the dark side of postmodern pain medicine creating a postmodern patient autonomy

    Article • Journal of Pain Research, November 2018, Dove Medical Press

    jan keppel hesselink, Dr Michael E. Schatman

  2. Phenytoin and carbamazepine in trigeminal neuralgia: marketing-based versus evidence-based treatment

    Article • Journal of Pain Research, July 2017, Dove Medical Press

    jan keppel hesselink, Dr Michael E. Schatman

  3. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain

    Article • Journal of Pain Research, February 2017, Dove Medical Press

    jan keppel hesselink, Dr Michael E. Schatman

  4. New topical treatment of vulvodynia based on the pathogenetic role of cross talk between nociceptors, immunocompetent cells, and epithelial cells

    Article • Journal of Pain Research, October 2016, Dove Medical Press

    Mr David Jos Kopsky, jan keppel hesselink

  5. The Role of Palmitoylethanolamide, an Autacoid, in the Symptomatic Treatment of Muscle Cramps: Three Case Reports and Review of Literature

    Article • Journal of Clinical Case Reports, January 2016, OMICS Publishing Group

    jan keppel hesselink

  6. Natural compound palmitoylethanolamide helps in sciatic pain and carpal tunnel syndrome

    Article • Journal of Pain Research, October 2015, Dove Medical Press

    jan keppel hesselink, Mr David Jos Kopsky

  7. Increasing the Degrees of Freedom for Treating Painful Diabetic Neuropathy

    Article • Journal of Pain & Relief, January 2015, OMICS Publishing Group

    jan keppel hesselink

  8. Walking with Neuropathic Pain: Paradoxical Shift from Burden to Support?

    Article • Case Reports in Medicine, January 2015, Hindawi Publishing Corporation

    jan keppel hesselink

  9. Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy

    Article • Journal of Ophthalmology, January 2015, Hindawi Publishing Corporation

    jan keppel hesselink

  10. Palmitoylethanolamide and baclofen cream helps in vagina pain syndrome

    Article • Archives of Gynecology and Obstetrics, April 2014, Springer Science + Business Media

    jan keppel hesselink, Mr David Jos Kopsky

  11. Pain Management

    Article • January 2014, Springer Science + Business Media

    jan keppel hesselink

  12. Palmitoylethanolamide (PEA)—‘Promiscuous’ anti-inflammatory and analgesic molecule at the interface between nutrition and pharma

    Article • PharmaNutrition, January 2014, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky, Professor Renger Witkamp

  13. Neuropathic Pain as a Result of Acromegaly, Treated With Topical Baclofen Cream

    Article • Journal of Pain and Symptom Management, October 2013, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky

  14. Idiopathic neuropathy and pain can be treated with the supplement palmitoylethanolamide

    Article • International Medical Case Reports Journal, September 2013, Taylor & Francis

    jan keppel hesselink

  15. Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical

    Article • Journal of Pain Research, August 2013, Taylor & Francis

    jan keppel hesselink

  16. Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells

    Article • Journal of Pain Research, March 2013, Taylor & Francis

    jan keppel hesselink, Mr David Jos Kopsky

  17. Analgesics without side-effects and how to use palmitoylethanolamide and alpha-lipoic acid!

    Article • Journal of Pain & Relief, January 2013, OMICS Publishing Group

    jan keppel hesselink

  18. Chemotherapy induced neuropathic pain treated with neuroprotectant palmitoylethanolamide

    Article • Chemotherapy Open access, January 2013, OMICS Publishing Group

    jan keppel hesselink

  19. Professor Rita Levi-Montalcini on Nerve Growth Factor, Mast Cells and Palmitoylethanolamide, an Endogenous Anti-Inflammatory and Analgesic Compound

    Article • Journal of Pain & Relief, January 2013, OMICS Publishing Group

    jan keppel hesselink

  20. Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold

    Article • International Journal of Inflammation, January 2013, Hindawi Publishing Corporation

    jan keppel hesselink, Professor Renger Witkamp

  21. Palmitoylethanolamide: a supplement effective in chronic pain

    Article • Journal of Pain Research, October 2012, Taylor & Francis

    jan keppel hesselink

  22. Intractable Neuropathic Pain in Spinal Intramedullary Cavernoma Treated Successfully with a Novel Combination Cream

    Article • Pain Medicine, May 2012, Oxford University Press (OUP)

    jan keppel hesselink, Mr David Jos Kopsky

  23. New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide

    Article • The Open Pain Journal, February 2012, Bentham Science Publishers

    jan keppel hesselink

  24. Intractable neuropathic pain due to ulnar nerve entrapment treated with cannabis and ketamine 10%

    Article • Journal of Clinical Anesthesia, February 2012, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky

  25. Central Neuropathic Pain in a Patient with Multiple Sclerosis Treated Successfully with Topical Amitriptyline

    Article • Case Reports in Medicine, January 2012, Hindawi Publishing Corporation

    jan keppel hesselink, Mr David Jos Kopsky

  26. Effectiveness of the association micronized N-palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, December 2011, Elsevier

    jan keppel hesselink

  27. Reply to “Letter to Editor” by Keppel Hesselink JM “Effectiveness of the association micronized N-palmitoylethanolamine (PEA)–transpolydatin in the treatment of chronic pelvic pain”

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, December 2011, Elsevier

    jan keppel hesselink

  28. High Doses of Topical Amitriptyline in Neuropathic Pain: Two Cases and Literature Review

    Article • Pain Practice, June 2011, Wiley

    jan keppel hesselink, Mr David Jos Kopsky

  29. Topical Amitriptyline in Post-Traumatic Neuropathic Pain

    Article • Journal of Pain and Symptom Management, April 2011, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky

  30. Multimodal Stepped Care Approach Involving Topical Analgesics for Severe Intractable Neuropathic Pain in CRPS Type 1: A Case Report

    Article • Case Reports in Medicine, January 2011, Hindawi Publishing Corporation

    jan keppel hesselink, Mr David Jos Kopsky

  31. Letter to the Editor

    Article • Current Therapeutic Research, December 2010, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky

  32. An integrative medicine approach for the treatment of neuropathic pain

    Article • European Journal of Integrative Medicine, December 2010, Elsevier

    jan keppel hesselink

  33. A quality indicator for CAM interventions: The IOCOB traffic light grading system

    Article • European Journal of Integrative Medicine, December 2010, Elsevier

    jan keppel hesselink

  34. Nerve Regeneration in Neuropathic Pain

    Article • Pain Medicine, October 2010, Oxford University Press (OUP)

    jan keppel hesselink, Mr David Jos Kopsky

  35. A New Combination Cream for the Treatment of Severe Neuropathic Pain

    Article • Journal of Pain and Symptom Management, February 2010, Elsevier

    jan keppel hesselink, Mr David Jos Kopsky

  36. St John's Wort and its Active Principles in Dipression and Anxiety. W. E. Müller. Birkhausen Verlag: Basel, Switzerland. 2005. ISBN 3-7643-6160-3. Pages 188.

    Article • Human Psychopharmacology Clinical and Experimental, November 2005, Wiley

    jan keppel hesselink

  37. Clinical Research on Acupuncture: Part 1. What Have Reviews of the Efficacy and Safety of Acupuncture Told Us So Far?

    Article • The Journal of Alternative and Complementary Medicine, June 2004, Mary Ann Liebert Inc

    jan keppel hesselink

  38. Concise guide to the cytochrome P450 system. Drug interaction principles for medical practice. Kelly L. Cozza and Scott C. Armstrong. American Psychiatric Publishing, Washington DC, 2001. Pages: 272. ISBN: 1‐58562‐000‐9. Paperback. Price: £25.50

    Article • Human Psychopharmacology Clinical and Experimental, January 2002, Wiley

    jan keppel hesselink

  39. Dance-drugs en cybercultuur

    Article • Psychopraxis, December 1999, Springer Science + Business Media

    jan keppel hesselink

  40. De toekomstige medicamenteuze behandeling van de ziekte van Alzheimer: van symptomatische naar causale therapie

    Article • Neuropraxis, August 1998, Springer Science + Business Media

    jan keppel hesselink

  41. Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants

    Article • The International Journal of Neuropsychopharmacology, July 1998, Oxford University Press (OUP)

    jan keppel hesselink

  42. Evolution of concepts and definitions of Parkinson's disease since 1817*

    Article • Journal of the History of the Neurosciences, June 1996, Taylor & Francis

    jan keppel hesselink

  43. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder

    Article • International Clinical Psychopharmacology, November 1995, Wolters Kluwer Health

    jan keppel hesselink

  44. The role of tumour necrosis factor α in the pathogenesis of multiple sclerosis, and pentoxifylline as a possible pharmacotherapeutic intervention

    Article • European Journal of Neurology, July 1995, Wiley

    jan keppel hesselink

  45. Ipsapirone in the treatment of bulimia nervosa: An open pilot study

    Article • International Journal of Eating Disorders, May 1995, Wiley

    jan keppel hesselink

  46. Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands

    Article • International Review of Psychiatry, January 1995, Taylor & Francis

    jan keppel hesselink

  47. A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, May 1994, Elsevier

    jan keppel hesselink

  48. A Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Ipsapirone Versus Lorazepam in Patients With Generalized Anxiety Disorder

    Article • Journal of Clinical Psychopharmacology, December 1993, Wolters Kluwer Health

    jan keppel hesselink

  49. Serotonin and Parkinson's Disease

    Article • American Journal of Psychiatry, May 1993, American Psychiatric Association

    jan keppel hesselink

  50. Depression in the course of treatment of generalized anxiety disorder with lorazepam, ipsapirone, and placebo: Results from a multicenter trial

    Article • Depression, January 1993, Wiley

    jan keppel hesselink

  51. Letter to editor

    Article • Human Psychopharmacology Clinical and Experimental, November 1992, Wiley

    jan keppel hesselink

  52. Reversible motor neuron disease

    Article • Neurology, November 1992, Wolters Kluwer Health

    jan keppel hesselink

  53. Sertraline in the prevention of depression

    Article • The British Journal of Psychiatry, August 1992, Royal College of Psychiatrists

    jan keppel hesselink

  54. DOSE-FINDING STUDIES WITH IPSAPIRONE IN ANXIETY

    Article • Clinical Neuropharmacology, January 1992, Wolters Kluwer Health

    jan keppel hesselink

  55. Nimodipine tested in a human model of cerebral ischaemia

    Article • European Journal of Clinical Pharmacology, January 1991, Springer Science + Business Media

    jan keppel hesselink

  56. Letters to the editor

    Article • Movement Disorders, January 1989, Wiley

    jan keppel hesselink